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Abstract
Background—Bariatric surgery remains the most effective treatment for reducing adiposity and 
eliminating type 2 diabetes, however the mechanism(s) responsible have remained elusive. 
Peroxisome proliferator activated receptors (PPAR) encompass a family of nuclear hormone 
receptors that upon activation exert control of lipid metabolism, glucose regulation, and 
inflammation. Their role in adipose tissue following bariatric surgery remains undefined.
Materials and Methods—Subcutaneous adipose tissue biopsies and serum were obtained and 
evaluated from at time of surgery and on postoperative day 7 in patients randomized to Roux-en-Y 
gastric bypass (n=13) or matched caloric restriction (n=14), as well as patients undergoing vertical 
sleeve gastrectomy (n=33). Fat samples were evaluated for changes in gene expression, protein 
levels, β-oxidation, lipolysis, and cysteine oxidation.
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Results—Within 7 days, bariatric surgery acutely drives a change in the activity and expression 
of PPARγ and PPARδ in subcutaneous adipose tissue thereby attenuating lipid storage, increasing 
lipolysis and potentiating lipid oxidation. This unique metabolic alteration leads to changes in 
downstream PPARγ/δ targets including decreased expression of FABP4 and SCD1 with increased 
expression of carnitine palmitoyl transferase 1 (CPT1) and uncoupling protein 2 (UCP2). 
Increased expression of UCP2 not only facilitated fatty acid oxidation (increased 15-fold following 
surgery) but also regulated the subcutaneous adipose tissue redoxome by attenuating protein 
cysteine oxidation and reducing oxidative stress. The expression of UCP1, a mitochondrial protein 
responsible for the regulation of fatty acid oxidation and thermogenesis in beige and brown fat, 
was unaltered following surgery.
Conclusions—These results suggest that bariatric surgery initiates a novel metabolic shift in 
subcutaneous adipose tissue to oxidize fatty acids independently from the beiging process through 
regulation of PPAR isoforms. Further studies are required to understand the contribution of this 
shift in expression of PPAR isoforms as a contributor to weight loss following bariatric surgery.
Introduction
By the year 2040, global estimates of the prevalence of obesity-linked type 2 diabetes 
mellitus (T2DM) are approximately 640 million people worldwide1. The mainstay treatment 
remains weight loss achieved by lifestyle modifications and medications2. Unfortunately, 
these strategies have not shown durable success3,4. As an endocrine organ, adipose tissue 
plays an important role in the pathogenesis of obesity and T2DM, and hyperplastic 
adipocytes secrete a variety of fatty acids and adipokines to achieve homeostasis5. The most 
effective treatment for obesity and T2DM is bariatric surgery3,6,7. The two most common 
procedures are vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB)8. 
For both procedures, by one-week post-surgery, insulin sensitivity is significantly improved 
with only minimal weight loss9. However, the mechanism(s) responsible for such rapid 
metabolic changes after surgery has been incompletely characterized10.
The peroxisome proliferator-activated receptor γ (PPARγ) nuclear receptor plays a major 
role in controlling adipocyte lipid storage and insulin sensitivity11,12. PPARδ is also 
abundantly expressed in adipose tissue and promotes lipid utilization by upregulating genes 
involved in fatty acid oxidation, such as carnitine palmitoyltransferase 1 (CPT1)13,14. Herein 
we report on a novel surgically-driven pathway resulting in increased adipose fatty acid β-
oxidation derived from down-regulation of PPARγ and increased expression and activation 
of PPARδ. The switch in PPAR expression regulates several key target genes such as 
FABP4, SCD1, CPT1 and UCP2. Moreover, increased expression of uncoupling protein 2 
(UCP2) mediates a reduction in adipose tissue oxidative stress and changes the tissue 
redoxome profile.
Materials and Methods
Study design
The University of Minnesota and St. Cloud Hospital Institutional Review Boards approved 
all investigations and informed consent was obtained from each participant. Thirty-three 
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patients > 21 years of age and BMI ≥ 35.0 kg/m2 undergoing VSG were recruited and 
informed consent was obtained. Abdominal subcutaneous adipose tissue (SAT) biopsies 
from 20 of the VSG patients were processed for tissue analysis. Based on a treatment effect 
of −0.5 after VSG and 0.18 after hypocaloric restriction for total effect of 0.68, we estimated 
that 12 patients per group would allow us to detect at least a 40% difference of tissue protein 
level of FABP4 between groups with the power of 0.8 and alpha value of 0.05. The details of 
the study methods of the 27 patients recruited and randomized to RYGB (n=13; 3 males and 
10 females) or diet (n=14; 4 males and 10 females)have been published15. Briefly, inclusion 
criteria included men and women older than 21 years of age with a BMI ≥ 35.0 kg/m2, and 
meeting criteria by ADA standards for pre-diabetes or T2DM. We exclude patients with 
severe medical comorbidities, inability to under go surgery, patients with unanticipated 
surgical complications, and subjects on thiazolidinediones (TZD) as these are known to 
affect the PPAR pathways.
Clinical data
Demographic data on sex, age, and T2DM were collected for obese patients at the time of 
surgery and seven days following bariatric surgery. Weight and height were measured 
immediately prior to surgery (preop) and during the postoperative visit. Body mass index 
(BMI) was calculated as weight (kg) divided by height (m2).
Surgical Procedures
Details of the surgical procedures have been previously described15. With regards to the 
RYGB, a 20–30 mL vertically oriented gastric pouch was constructed using 3.5 mm staples. 
A 10–12 mm gastrojejunostomy was created in an antecolic, antegastric fashion, with the 
Roux limb measuring approximately 150 cm from the gastrojejunostomy. For the 
laparoscopic VSG, a 4.8 mm stapler load was used to divide the greater curvature of the 
stomach 5 cm from the pylorus and remaining 3 cm from the angularis incisura. 3.5 mm 
stapler loads were fired thereafter progressing up to the angle of His to complete the VSG.
Tissue sampling and blood collection
SAT samples and blood specimens were obtained from patients on the day of intervention 
and seven days post-intervention. Approximately 2–3 g of fat was obtained from each 
subject and either immediately frozen with liquid nitrogen and stored at −80°C or processed 
by collagenase digestion, or for measurements of β-oxidation and lipolysis.
Assessment of DM medication score and insulin resistance
Fasting plasma glucose and plasma insulin levels were obtained at the time of initiation of 
intervention and seven days post-intervention. Homeostasis Model of Assessment for Insulin 
Resistance (HOMA-IR) was calculated according to the method described by Matthews et 
al16. Hemoglobin A1c (HbA1c) was determined preoperatively on 20 patients (S. Table 1).
β-oxidation measurement in subcutaneous adipose tissue explants
Pre- and post-surgery SAT biopsies were minced and incubated with KRH buffer 
supplemented with 14C-palmitic acid for 1 h at 37°C. Minced tissue were transferred with 
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medium into a 20 ml-glass reaction vial, which has a 1 mL tube containing 400 μL of 1 M 
NaOH. Perchloric acid was added to stop the reaction, and samples were incubated for 1 h 
shaking at 80 rpm. 14CO2 was trapped into the central tube and measured by liquid 
scintillation counting.
Lipolysis measurement in human subcutaneous adipose tissue explants
0.3 g of adipose tissue was minced and incubated with 500 μl assay buffer at 37°C for 1 
hour. The tissue mixture was centrifuged at 500 × g for 10 minutes and the liquid between 
the pellet and floating adipose tissue was moved to a new tube. Free fatty acids were 
measured using kits obtained from Wako Diagnostics (Mountain View, CA) and glycerol 
was measured using a Glycerol Colorimetric Assay Kit from Cayman Chemical Company 
(Ann Arbor, MI), each sample was measured in triplicates and presented as a composite 
mean with standard error of the mean.
Collagenase Digestion
After fat was obtained, it was immediately minced and digested with type I collagenase in 
Krebs-Ringers-HEPES (KRH) buffer supplemented with 10 mg/ml bovine serum albumin 
(BSA). After incubation at 37°C for one hour, the mixture was filtered with a cell strainer 
(100-μm-pore-size nylon; Falcon) to remove undigested tissues. The stromal vascular 
fraction (SVF) was collected by centrifugation at 500 × g for 10 minutes and both fractions, 
the floating primary adipocyte and the SVF were washed, and TRIzol © (Invitrogen, 
Carlsbad, CA) reagent was used for RNA isolation.
Real-time PCR
Total RNA was extracted from approximately 0.3 g of adipose tissue using TRIzol © 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. After DNase 
treatment, cDNA was synthesized using iScript cDNA synthesis kit (BioRad, Hercules, CA). 
Relative quantification of mRNA was performed by RT-PCR using iQ SYBR green 
Supermix and the MyiQ detection system (BioRad, Hercules, CA). Each sample was 
measured in duplicate. Human primers for target genes are listed in Supplemental Table 3. 
Gene expression data are expressed as arbitrary units normalized to the reference gene 
hTBP.
Immunoblotting
Immunoblotting was performed as previously described17. Cells were lysed in 
radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitors. Equal 
amounts of protein were separated by SDS-PAGE and transferred to polyvinylidene 
difluoride (PVDF) membrane. After a blocking step, membranes were incubated with 
primary antibody overnight at 4°C. Membranes were washed and incubated with secondary 
antibody conjugated to Li-Cor IRDye for 1 h and visualized using Odyssey infrared imaging 
(Li-Cor Biosciences, Lincoln, NE). The antibodies used were anti-PPARγ (Santa Cruz, 
Dallas, Texas, sc-7273), anti-FABP4 (laboratory stock), anti-CD36 (R&D Systems, 
Minneapolis, MN, AF2519), anti-Perilipin1 (American Research Products, Waltham, MA, 
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03-651156), anti-sulfenic acid modified cysteine (Milipore, Darmstadt, Germany, ABS30) 
and anti-β-actin (Sigma-Aldrich, St. Louis, MO, A3854).
Mitochondrial isolation
Mitochondrial isolation was carried out as previously described17. Adipose tissue was 
minced in ice-cold mitochondrial isolation buffer (20 mM Tris pH 7.4, 220 mM mannitol, 70 
mM sucrose, 1 mM EDTA, 0.1 mM EGTA) and supplemented with protease inhibitors. The 
tissue was then further homogenized with 15 strokes of a Dounce homogenizer and 
centrifuged at 700 × g for 10 minutes at 4° C. Avoiding the lipid layer, the supernatant was 
transferred to a fresh tube and centrifuged at 10,000 × g for 15 min at 4° C.
Dimedone labeling of sulfenic acids
Mitochondria pellets were solubilized using sonication in radioimmunoprecipitation assay 
(RIPA) buffer containing protease inhibitors, 1 mM dimedone, 10 mM iodoacetamide, 
10mM N-ethylmaleimide, and 200 units/mL catalase to metabolize intracellular hydrogen 
peroxide. The lysates were incubated for 1 hr on ice followed by the addition of Laemmli 
protein sample buffer and the proteins were separated on an SDS-PAGE gel for cysteine 
oxidation (sulfenic acid) detection18.
ELISA measurement of serum FABP4
Serum FABP4 was measured with human FABP4 Quantikine ELISA kit from R&D systems 
(#DFBP40) according to the manufacturer’s instructions. Each sample was measured in 
duplicate.
Statistical analysis
The data are expressed as mean ± standard error. Statistical analysis was performed using 
unpaired two-sided Student’s t-test when comparing between groups and paired two-sided 
Student’s t-test to compare pre- and post-surgical measures within groups. Unadjusted 
Pearson correlations were calculated to evaluate relations between HbA1c and target of 
interest, and changes in FABP4 and hormone of interest. Data with p-values less than 0.05 
were considered statistically significant, unless otherwise stated.
Results
Expression of PPARγ and downstream targets decrease after bariatric surgery
VSG was initially performed on 20 subjects (Supplemental Table 1). One-week post-VSG, 
subjects had minimal, although statistically significant weight loss and an improved HOMA-
IR (Fig. 1A,B). Patients who were prediabetic or diabetic had higher initial HOMA-IR levels 
(5.3 ± 0.9) and exhibited a greater decrement in levels post-surgery (3.4 ± 0.5; P = 0.02).
SATPPARγ mRNA levels decreased significantly one-week after VSG, on average by 60% 
(Fig. 1C),along with several well-established PPARγ targets including fatty acid binding 
protein 4 (FABP4), phosphodiesterase 3B (PDE3B), adipose triglyceride lipase (ATGL), 
cluster of differentiation 36 (CD36), stearoyl-CoA desaturase 1 (SCD1), uncoupling protein 
1 (UCP1) and perilipin 1 (Fig. 1D). Assessment of PPARγ protein levels indicated a similar 
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trend (P = 0.09), on average decreasing by nearly 60% (Fig. 1E). Furthermore, protein levels 
of CD36 also decreased significantly whereas Perilipin 1 trended downward (Fig. 1E).
To identify which cell population(s) was responsible for the decreased expression of PPARγ 
and its gene targets, we performed collagenase digestion of SAT to obtain a primary 
adipocyte fraction (ADIP) and SVF. mRNA levels of PPARγ and its downstream targets 
were consistently decreased in both fractions. One notable exception was PDE3B mRNA, 
although decreased in ADIP, was nearly tripled in SVF (Fig. 1F,G).
In addition to VSG, RYGB is a commonly performed bariatric procedure that adds a 
malabsorptive component to the treatment19. We previously performed a study that 
randomized obese diabetic subjects to RYGB versus a hypocaloric matched diet15. Weight 
loss after RYGB was similar to that observed following VSG (Fig. S1A). The RYGB group 
had a higher HbA1c and was on more anti-diabetic medications than the VSG cohort15. 
While there was no decrease in PPARγ gene expression in post-RYGB patients, several 
PPARγ gene targets including PDE3B, ATGL, SCD1, and UCP1 decreased significantly or 
trended towards reduced levels (Fig. S1C). Protein levels of PPARγ and its downstream 
targets, CD36 and Perilipin 1, decreased or trended downward after RYGB, similar to that 
seen post-VSG (Fig. S1D).
In an attempt to reconcile the differences in diabetic status among our patients undergoing 
VSG as compared to RYGB, we pooled all surgical patient data together and evaluated 
whether preoperative diabetic status, specifically HbA1c or HOMA-IR, was associated with 
acute post-surgical differences in PPARγ gene expression and that of its downstream targets. 
HbA1c strongly correlated with changes in mRNA levels of PPARγ (Fig. S2A). HbA1c also 
correlated with several downstream targets, specifically FABP4, PDE3B, and CD36, but not 
with ATGL or SCD1 (Fig. S2B–F). These findings suggest that acutely after surgery, 
patients with higher preoperative HbA1c have smaller changes in PPARγ and downstream 
targets. As such, both bariatric procedures result in decreased adipose PPARγ activity, an 
effect previously suggested to improve insulin sensitivity20,21.
Expression of PPARδ and its targets increase after bariatric surgery
PPARδ activity supports lipid metabolism in adipose and muscle via regulation of genes 
involved in fatty acid uptake, β-oxidation, and energy uncoupling. After VSG and RYGB, 
the expression of PPARδ increased 2–3 fold in SAT (Fig. 2A, Fig. S4A). Furthermore, 
several downstream targets of PPARδ, including CPT1, pyruvate dehydrogenase kinase 4 
(PDK4), perilipin 2, and angiopoietin like 4 (ANGPLT4), increased significantly after VSG 
(Fig. 2B–E). After RYGB, CPT1 increased while PDK4 did not change (Fig. S4B,C). In 
contrast to PPARγ, changes in PPARδ and CPT1 did not correlate with preoperative HbA1c 
(Fig. S2H,I). PPARα, another participant in lipid metabolism, and its downstream target, 
CPT2, were unchanged after bariatric surgery or hypocaloric diet (Fig. 2F,G and Fig. 
S4D,E). Overall, bariatric surgery is associated with a dramatic change in the expression and 
activity PPARγ and PPARδ in SAT resulting in reduced gene expression of enzymes and 
proteins associated with lipid synthesis in favor of those linked to lipid oxidation.
Jahansouz et al. Page 6
Int J Obes (Lond). Author manuscript; available in PMC 2018 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Caloric restriction does not regulate PPARγ or PPARδ activity
It has been demonstrated that plasma glucose and insulin levels decrease as early as one-
week after bariatric surgery prior to substantial weight loss and independent of diet9. To 
assess whether the observed post-surgical effects on PPARγ or PPARδ were dependent upon 
caloric restriction, we performed our analysis on a calorically restricted group from our 
previous randomized controlled trial15.
Although acute weight loss after hypocaloric restriction was similar to that observed in the 
surgical cohorts (Fig. S3A), there was no change in subcutaneous adipose PPARγ mRNA 
levels (Fig. S3B). Evaluations of adipose expression of PPARγ targets following 
hypocaloric restriction revealed increases in PDE3B and FABP4, decreases in SCD1, and no 
change in UCP1 (Fig. S3C). In contrast to the surgical groups, PPARγ protein levels 
increased five-fold after hypocaloric restriction, without changes to CD36 or Perilipin 1 
(Fig. S3D). Similarly, neither expression of PPARδ nor its downstream targets changed after 
hypocaloric diet (Fig. S4A–C). As such caloric restriction does not induce a similar change 
in the activity of PPARγ or PPARδ as does bariatric surgery.
Adipose tissue β-oxidation and lipolysis increase following VSG
To explore the functional consequences of increased PPARδ activity, we measured β-
oxidation in adipose tissue explants from six additional subjects undergoing VSG (S. Table 
2) using 14C-palmitate oxidation. Consistent with the upregulation of PPARδ activity and 
targets, β-oxidation was increased 15-fold following VSG (Fig. 3A). One potential 
contributor of β-oxidation is increased fatty acid availability via increased lipolysis22. 
Indeed, previous reports have shown via hyperinsulinemic-euglycemic clamps that lipolysis 
is increased after bariatric surgery9,23. Similar to that shown by Gastaldelli et al. and 
Camastra et al. following RYGB, adipose tissue explants obtained from seven VSG subjects 
(S. Table 2) one week after VSG demonstrated a 2-fold increase in lipolysis (Fig. 3B–D)9,23.
These results suggest that increased lipid mobilization following VSG leads to increased 
fatty acid oxidation within WAT. This increase in lipid oxidation does not appear to be due 
to beiging or browning since UCP1 was not upregulated after bariatric surgery and indeed, 
shows a strong trend towards being downregulated (Fig. 1D, Fig. S1C).
Bariatric surgery downregulates FABP4 and upregulatesFABP5
Fatty acid binding proteins, notably FABP4 and FABP5, play critical roles in lipid 
metabolism and are PPARγ and PPARδ targets, respectively24. As shown in Fig. 4A and B, 
adipose FABP4 protein decreased nearly 40% per patient post–VSG. Although FABP4 
mRNA levels did not significantly change in the RYGB population, protein levels dropped 
by nearly 20% (Fig. 4A,B). FABP4 protein levels did not change in the diet cohort. FABP4 
has also been identified as a circulating adipokine that could contribute to systemic insulin 
resistance through actions on liver and pancreatic β-cells25,26. Therefore, we measured the 
serum levels of FABP4 in the three cohorts one-week after intervention. While serum levels 
of FABP4 did not change in either the VSG or RYGB cohorts, they were increased by about 
30% in the diet cohort (Fig. S5). Protein levels of FABP5, another fatty acid carrier in 
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adipose tissue and a PPARδ target, increased after both VSG and RYGB (Fig. S6A,B), but 
not in the diet group (Fig. S6C).
Thus, consistent with altered expression of PPAR isoforms, there is an acute switch in lipid 
carrier proteins after bariatric surgery that results in the downregulation of FABP4 and 
upregulation of FABP5 in SAT. While FABP4 expression decreases in adipose tissue, a 
compensatory upregulation of FABP5 was observed. Interestingly, FABP5 has been reported 
to deliver ligands to activate PPARδ, resulting in increased expression of genes involved in 
β-oxidation27.
Bariatric surgery increases UCP2 levels and decreases cysteine oxidation in SAT
We have previously demonstrated that reduced inflammation resulting from decreased 
FABP4 expression is dependent upon the upregulation of UCP217 and UCP2 has also been 
identified as a downstream target of PPARδ in a number of different tissues28. As shown in 
Fig. 4C, UCP2 expression increased approximately 7-fold following VSG and 3-fold 
following RYGB, but did not change in the diet cohort. Furthermore, UCP2 was upregulated 
in both ADIP and SVF in VSG (Fig. 4D). The changes in gene expression of UCP2 
following surgery correlated with preoperative HbA1c (Fig. S2G).UCP2 exerts its cellular 
function, in part, by reducing reactive oxygen species (ROS) which, if left unchecked, can 
alter a variety of cellular functions by oxidizing protein residues such as cysteines29. 
Consistent with the upregulation of UCP2, we observed reduced cysteine oxidation in 
adipose tissue following VSG (Fig. 5A,B).
Discussion
Bariatric surgery is the most efficacious treatment of two of the most burdensome diseases in 
healthcare today: obesity and T2DM3,4. Here we report a novel finding of altered expression 
of PPARγ and PPARδ occurring acutely in subcutaneous adipose tissue of human subjects 
after bariatric surgery, independent of caloric restriction. This alteration in the main 
regulators of adipose tissue metabolism has important implications in energy metabolism 
and insulin sensitivity given the active role of SAT. While visceral adipose tissue has been 
considered the primary metabolically active depot, evidence suggests that SAT is also 
critical to overall energy metabolism, even serving as the preferred storage depot in 
postprandial states30. Furthermore, in a comparison of multiple weight loss interventions 
including bariatric surgery, SAT loss was consistently observed to be greater than visceral 
adipose tissue loss, and visceral fat loss was linked to subcutaneous fat loss31.
PPARγ in particular is a major mediator of adipose tissue biology and increasing the activity 
of PPARγ via TZDs has traditionally been considered insulin sensitizing. Paradoxically, 
humans with a less active PPARγ (Pro12Ala), also have improved glucose homeostasis and 
are metabolically protected against T2DM32,33. Furthermore, given its adipogenic function, 
increasing PPARγ activity has the side effect of weight gain34. Based on our findings of 
reduced PPARγ activity following both RYGB and VSG surgeries, TZDs may be 
mechanistically counterproductive to the beneficial effects of bariatric surgery.
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The decreased adipose PPARγ expression and activity post-surgery indicates an acute 
metabolic switch that favors the use of adipose tissue for energy dissipation rather than for 
energy storage. Supporting this concept, increased PPARδ activity favors lipid utilization via 
increased fatty acid oxidation and energy uncoupling13. Indeed, in several mouse models 
exhibiting increased lipolysis in WAT, there is a concurrent increase in white adipose tissue 
PPARδ and UCP2 expression that drives fatty acid oxidation and thermogenesis35–37. 
Furthermore, these models do not exhibit elevated serum free fatty acids or hepatic/skeletal 
muscle fatty acid oxidation demonstrating the important role that adipocyte fatty acid 
oxidation can play in overall energy metabolism and adiposity35–37. Consistent with this, we 
observed a 15-fold increase in WAT fatty acid oxidation, increased lipolysis, and decreased 
serum fatty acids post-surgery. Fatty acid oxidation in WAT has been underappreciated since 
most lipolysis-liberated fatty acids are re-esterified or released under normal physiological 
conditions18. Fasting has been demonstrated to increase fatty acid oxidation in adipocytes by 
2-fold18. Considering the surplus of triglycerides stored in adipose tissue of obese patients, a 
slight increase of the oxidation pathway over time might influence whole body energy 
balance. Further studies are required to understand the contribution of the increase in PPARδ 
activity as a contributor to weight loss following bariatric surgery. Our study demonstrates a 
dramatic increase in adipose tissue FFA disposal through an oxidative pathway post-bariatric 
surgery, independently from SAT browning via UCP1 expression. This not only sheds light 
on potential mechanisms of the surgery in adipose tissue, but also provides support for 
therapeutic targets for the medical management of diabetes. Indeed, a PPARδ agonist has 
shown promise in clinical trials with regards to lipid metabolism38. In fact, a study that 
randomized patients to a PPARδ agonist or placebo found improvements in metabolic 
syndrome in PPARδ recipients38. While this study focused on the effects of PPARδ agonism 
on skeletal muscle, our findings suggest that adipose tissue may play a role in this 
improvement as well. Further evaluation is needed to clarify the effect of PPARδ agonism in 
SAT.
Decreased levels of FABP4 have been associated with improved insulin sensitivity in both 
humans and mice39–41. A polymorphism at the promoter region of FABP4, which leads to a 
decrease of about 60% in expression, has been associated with a decreased risk of type 2 
diabetes and cardiovascular disease42. In this study, we observed an average reduction of 
40% and 20% of FABP4 protein levels after VSG and RYGB, respectively, independent of 
caloric restriction. Interestingly, FABP4 expression has been shown to decrease WAT fatty 
acid oxidation43. Therefore, decreased FABP4 post-surgery is consistent with increased β-
oxidation. The increased fatty acid oxidation could generate mitochondrial reactive oxygen 
species44. However, Xu et al. as well as Steen et al. previously identified an inverse 
relationship between FABP4 and UCP217,45,46. Indeed, the expression of UCP2, a 
downstream target of PPARδ, was increased over 7-fold in WAT after bariatric surgery. 
Notably, a polymorphism in the promoter region of UCP2 that increases its expression has 
been linked to a reduced risk of obesity and diabetes in humans47–49.This dramatic increase 
of UCP2 would be predicted to reduce ROS levels. Supportive of this, mitochondrial protein 
cysteine oxidation was decreased after bariatric surgery. As such, bariatric surgery results in 
a decrease in oxidative stress in adipose tissue. Although the current study focused on early 
changes after bariatric surgery, there is evidence of persistence of this pathway 
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longitudinally. Affonso et al. reported increased UCP2 expression in SAT of patients 6 
months following RYGB and correlated this change with increased resting metabolic rate50. 
Moreover, Simón et al. as well as Terra et al. found decreased serum FABP4 levels at 6 and 
12 months following RYGB51,52. Surprisingly, Engl and colleagues observed no change in 
serum FABP4 levels despite 25 kg weight loss at one year after laparoscopic gastric band 
placement, a purely dietary restrictive bariatric procedure. These studies in conjunction with 
our observations support a reduction in FABP4 that may be uniquely associated with 
bariatric surgery and not necessarily with caloric restriction alone53. As such, the 
downregulation of FABP4 may potentially serve as a biomarker to predict longitudinal 
outcomes.
In summary, we have identified a novel alteration in the activity of PPARγ and PPARδ that 
leads to the downregulation of FABP4 and upregulation of UCP2 in subcutaneous adipose 
tissue after bariatric surgery. The altered expression of these molecular regulators leads to a 
metabolic shift in adipose tissue involving an increase of white adipose tissue lipolysis, lipid 
utilization through adipose fatty acid oxidation, and the control of ROS via UCP2 activity 
that in sum may contribute to the benefits of bariatric surgery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
VSG downregulates PPARγ and PPARγ target expression in adipose tissue. (A) Body 
weight of patients pre- and one-week post-VSG (n=20); (B) HOMA-IR of patients pre- and 
one-week post-VSG; (C) Relative PPARγ mRNA levels in SAT pre- and one-week post-
VSG (n=12); (D) Relative mRNA levels of FABP4 (fatty acid binding protein 4), PDE3B 
(phosphodiesterase 3B), ATGL (adipose triglyceride lipase), CD36 (cluster of differentiation 
36), SCD (stearoyl-CoA desaturase 1), UCP1 (uncoupling protein 1) in SAT pre- and one-
week post-VSG (n=12); (E) Protein levels of PPARγ, CD36, and Perilipin 1 measured by 
western blot in adipose tissue of patients pre- and one-week post-VSG (n=4); (F) mRNA 
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levels of PPARγ, FABP4, PDE3B, CD36, and SCD in the primary adipocyte fraction of SAT 
of patients pre- and one-week post-VSG (n=8); (G) mRNA levels of PPARγ, FABP4, 
PDE3B, CD36, and SCD1 in stromal vascular fraction of SAT of patients pre- and one-week 
post-VSG (n=8). * denotes p<0.05; ** denotes p<0.01.
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Figure 2. 
VSG upregulates PPARδ and PPARδ target expression in adipose tissue. Relative mRNA 
levels in SAT of subjects pre- and one week post-VSG (n=12) of (A) PPARδ; (B) CPT1; (C) 
PDK4; (D) Perilipin2; (E) ANGPLT4; (F) PPARα; (G) CPT2. * denotes p<0.05; ** denotes 
p<0.01.
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Figure 3. 
VSG increases adipose tissue fatty acid oxidation and lipolysis. (A) β-oxidation measured in 
SAT pre- and post-VSG (n=6); (B) Secreted fatty acids measured in SAT pre- and post-VSG 
(n=7); (C) Secreted glycerol measured in SAT pre- and post-VSG (n=7); (D) Ratio of 
secreted fatty acids to glycerol from SAT pre- and post-VSG (n=7). ** denotes p<0.01.
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Figure 4. 
The downregulation of FABP4 and upregulation of UCP2 occurs in SAT of patients 
following bariatric surgery, but not after caloric restriction. (A–B) SAT FABP4 protein levels 
as determined by western blot in patients pre- and post-VSG (n=6), RYGB (n=9), and 
caloric restriction (n=10). (C) SAT expression of UCP2 mRNA in patients pre- and post-
VSG (n=12), RYGB (n=13), and caloric restriction (n=14), as determined by qRT-PCR; (D) 
mRNA levels of UCP2 in the primary adipocyte fraction (ADIP) and stromal vascular 
fraction (SVF) in SAT of patients pre- and 7 days post-VSG (n=8). * denotes p<0.05; ** 
denotes p<0.01.
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Figure 5. 
Cysteine oxidation in SAT was decreased 7 days following VSG; (A) SAT cysteine 
oxidation levels in patients pre- and post-VSG (n=5); (B) Quantification of cysteine 
oxidation levels in SAT of patients pre- and post-VSG. Total intensity of cysteine oxidation 
was normalized to total protein for each sample using Ponceau S staining solution. * denotes 
p<0.05.
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